<DOC>
	<DOCNO>NCT01224795</DOCNO>
	<brief_summary>This study evaluate efficacy safety single dose intravenous peramivir versus placebo adolescent adult acute uncomplicated influenza .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Intravenous Peramivir Subjects With Uncomplicated Influenza .</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled study evaluate efficacy safety single dose intravenous peramivir versus placebo adolescent adult acute , uncomplicated influenza .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Peramivir</mesh_term>
	<criteria>Male nonpregnant female subject age ≥12 year . Test positive influenza A B Rapid Antigen Test ( RAT ) perform commercially available test adequate anterior nasal specimen accordance manufacturer 's instruction . Presence least one respiratory symptom ( cough , sore throat , nasal symptom ) least moderate severity . Presence least one constitutional symptom ( myalgia [ ache pain ] , headache , feverishness , fatigue ) least moderate severity . Onset symptoms 36 hour presentation screen . Written inform consent/assent . Women pregnant breastfeeding . Employees study site , immediate family member study site employee . Presence clinically significant sign acute respiratory distress . History severe chronic obstructive pulmonary disease ( COPD ) severe persistent asthma . History heart failure angina require daily pharmacotherapy symptom consistent New York Heart Association Class III IV functional status within past 12 month . History chronic renal impairment require hemodialysis and/or know suspected moderate severe renal impairment ( actual estimate creatinine clearance &lt; 50 mL/min ) . Clinical evidence worsen chronic medical condition ( temporally associate onset symptom influenza ) , investigator 's opinion , indicate find ( ) could represent complication influenza . Current clinical evidence , include clinical sign and/or symptom consistent otitis medium , bronchitis , sinusitis and/or pneumonia , active bacterial infection body site require therapy oral systemic antibiotic . Presence immunocompromised status due chronic illness , previous organ transplant , use immunosuppressive medical therapy would include oral systemic treatment &gt; 10 mg ic treatment &gt; 10 mg prednisone equivalent daily basis within 30 day screen . Presence known HIV infection CD4 count &lt; 350 cell/mm3 . Receipt dose rimantadine , amantadine , zanamivir , oseltamivir 7 day prior screen . Immunization influenza live attenuate virus vaccine ( FluMist® ) previous 21 day . History alcohol abuse drug addiction within 1 year prior admission study . Participation previous study intramuscular intravenous peramivir , previous exposure peramivir . Participation study investigational drug device within last 30 day . Presence preexist illness , opinion investigator , would place subject unreasonably increase risk participation study . Presence preexist illness opinion investigator would make subject unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>uncomplicated influenza</keyword>
</DOC>